The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...